8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2010

ALIMERA SCIENCES, INC.

(Exact name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

001-34703
(Commission File No.) 20-0028718
(IRS Employer Identification No.)

6120 Windward Parkway
Suite 290
Alpharetta, Georgia 30005
(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (678) 990-5740

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
	Item 9.01. Financial Statements and Exhibits.
SIGNATURES
EX-99.1

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     On August 16, 2010, Alimera Sciences, Inc. (the “Company”) issued a press release announcing the promotions of Richard S. Eiswirth, Jr. to Chief Operating Officer and David R. Holland to Senior Vice President of Sales and Marketing. These promotions will be effective as of August 11, 2010, the date on which they were approved by the Company’s board of directors. In addition to his new role, Mr. Eiswirth will retain his position as the Company’s Chief Financial Officer. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     As a result of these promotions, Mr. Eiswirth’s 2010 salary has been increased to $299,000 and Mr. Holland’s salary has been increased to $273,000. The compensation committee of the Company’s board of directors will continue to evaluate the compensation of the Company’s executive officers and may make further changes as it deems appropriate. The committee has engaged a compensation consultant to advise it with respect to these matters.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
	99.1	Press Release of Alimera Sciences, Inc. dated August 16, 2010.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALIMERA SCIENCES, INC.
By:	/s/ RICHARD S. EISWIRTH, JR.
	Name:	Richard S. Eiswirth, Jr.
	Title:	Chief Financial Officer and Chief Operating Officer

Dated: August 16, 2010

EX-99.1

Exhibit 99.1

Katie Brazel	FOR IMMEDIATE RELEASE
Fleishman Hillard
404.739.0150
Katie.Brazel@fleishman.com

ALIMERA SCIENCES ANNOUNCES KEY EXECUTIVE PROMOTIONS

ATLANTA (August 16, 2010) — Alimera Sciences, Inc., (NASDAQ: ALIM), (“Alimera”), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the promotions of Richard S. Eiswirth, Jr. to chief operating officer, and David R. Holland to senior vice president of sales and marketing. Mr. Eiswirth, who retains the position of chief financial officer in addition to his new role, will continue to oversee Alimera’s finances and growth strategy implementation. Mr. Holland, a co-founder of Alimera who has served as vice president of marketing since 2003, will manage corporate communications and product sales and marketing, including managed markets, professional and consumer outreach, advertising and public relations.

At the end of the year, Alimera expects to receive an action letter from the FDA in response to its New Drug Application for its intravitreal insert, Iluvien^®, for the treatment of diabetic macular edema. In their expanded roles, Messrs. Eiswirth and Holland will guide the U.S. commercialization of Iluvien.

“Alimera Sciences is on the brink of providing a much needed long-term treatment for diabetic macular edema, and it is essential to appropriately align our resources and delineate responsibilities for this endeavor,” said Dan Myers, Alimera’s president and CEO. “I am pleased to announce the promotions of Rick and Dave, whose hard work and dedication have been integral to the growth and success of our company. I am confident they will make significant contributions as we plan for and execute the Iluvien launch.”

Prior to joining Alimera in 2006, Mr. Eiswirth, a Wake Forest University graduate, founded two consulting practices, Brand Ignition Group and Black River Holdings, Inc., and served as the CFO and senior executive vice president of Netzee, Inc. Mr. Eiswirth currently serves as the chairman of the board and of the audit committee for Jones Soda, Inc., a Seattle-based beverage company. Mr. Holland, who graduated from Princeton University, spent 18 years marketing ethically promoted, over-the-counter and prescription pharmaceuticals for companies including Novartis, CIBA Vision and Procter and Gamble before co-founding Alimera.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently, the Company is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate, Iluvien^®, is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema, a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.

Forward Looking Statements

This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s future results of operations and financial position, business strategy and plans and objectives of management for Alimera’s future operations. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “likely,” “will,” “would,” “could,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The events and circumstances reflected in Alimera’s forward-looking statements may not occur and actual results could differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, delay in or failure to obtain regulatory approval of Alimera’s product candidates, uncertainty as to Alimera’s ability to commercialize, and market acceptance of, its product candidates, the extent of government regulations, uncertainty as to relationship between the benefits of Alimera’s product candidates and the risks of their side-effect profiles, dependence on third-party manufacturers to manufacture Alimera’s product candidates in sufficient quantities and quality, uncertainty of clinical trial results, limited sales and marketing infrastructure, as well as other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s quarterly reports on Form 10-Q for the quarters ended March 31, 2010 and June 30, 2010, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov.

All forward-looking statements contained in this press release are expressly qualified by the above paragraph in their entirety. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

###